Castle Biosciences Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Castle Biosciences Inc. has filed its 2023 10-K, providing a comprehensive overview of its financial health and operational landscape.</b>

AI Summary

CASTLE BIOSCIENCES INC (CSTL) filed a Annual Report (10-K) with the SEC on February 28, 2024. Castle Biosciences Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The filing details financial performance, business operations, and risk factors for the company. Key financial data from the report will provide insights into revenue, profitability, and balance sheet health. The report includes information on executive compensation and stock-based payment plans. Specific risk factors related to third-party payor concentration and market dynamics are outlined.

Why It Matters

For investors and stakeholders tracking CASTLE BIOSCIENCES INC, this filing contains several important signals. This 10-K filing is crucial for investors to assess the company's financial performance and strategic direction over the past fiscal year. Understanding the detailed risk factors and executive compensation structures will help stakeholders evaluate potential challenges and management's alignment with shareholder interests.

Risk Assessment

Risk Level: medium — CASTLE BIOSCIENCES INC shows moderate risk based on this filing. The company faces medium risk due to its reliance on third-party payors, including Medicare, as highlighted in the filing regarding revenue concentration.

Analyst Insight

Investors should analyze the revenue growth and profitability trends presented in the 10-K to determine the company's future prospects.

Executive Compensation

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-02-28 — Filing Date (Date of submission)
• 0001447362-24-000017 — Accession Number (SEC filing identifier)
• 001-38984 — SEC File Number (Company's SEC file number)

Key Players & Entities

• CASTLE BIOSCIENCES INC (company) — Filer
• 20231231 (date) — Fiscal year end
• 20240228 (date) — Filing date
• 505 S FRIENDSWOOD DRIVE (address) — Business address
• 866-788-9007 (phone) — Business phone
• Medicare (company) — Third-party payor
• Payor A (company) — Third-party payor
• Frank Stokes (person) — Executive

FAQ

Risk Factors

• Third-Party Payor Concentration Risk [medium — financial]: The company faces risks related to its concentration of revenue from third-party payors, including Medicare and Payor A.

Industry Context

Castle Biosciences Inc. operates in the medical laboratories sector, focusing on diagnostic tests for skin conditions.

Regulatory Implications

The company's operations are subject to regulatory oversight, particularly concerning reimbursement from third-party payors like Medicare.

What Investors Should Do

1. Review the detailed financial statements for revenue trends and profitability.
2. Analyze the identified risk factors, especially those related to payor concentration.
3. Examine executive compensation and stock-based plans for alignment with company performance.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-02-28: Filing Date — Date the 10-K was officially filed with the SEC.

Year-Over-Year Comparison

This filing represents the annual 10-K for the fiscal year 2023, providing a comprehensive update compared to previous filings.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share CSTL The Nasdaq Glo
• $540 million — an estimated U.S. TAM of approximately $540 million. This estimated annual incidence number
• $820 million — an estimated U.S. TAM of approximately $820 million. DecisionDx-SCC is clinically validate
• $600 million — an estimated U.S. TAM of approximately $600 million. As of December 31, 2023, MyPath Melan
• $1 billion — an estimated U.S. TAM of approximately $1 billion. As of December 31, 2023, our TissueCy
• $10 million — an estimated U.S. TAM of approximately $10 million. DecisionDx-UM has been clinically val
• $5 billion — We estimate a U.S. TAM of approximately $5 billion associated with this test. We began off
• $1.9 billion — has the potential to add approximately $1.9 billion to our current estimated U.S. TAM. In t
• $5.7 billion — ur pipeline add an additional estimated $5.7 billion to our U.S. TAM. U.S. TAM is based on e
• $47.6 m — ng services, for total consideration of $47.6 million, consisting of $30.5 million in c
• $30.5 million — eration of $47.6 million, consisting of $30.5 million in cash and $17.1 million in shares of
• $17.1 million — consisting of $30.5 million in cash and $17.1 million in shares of our common stock, adding t
• $49.0 million — her platform for total consideration of $49.0 million. In May 2021, we acquired Myriad myPat
• $32.5 million — tics, Inc. for a cash purchase price of $32.5 million. 7 Table of Contents Test Report V

Filing Documents

• cstl-20231231.htm (10-K) — 2015KB
• exhibit1020severanceandcic.htm (EX-10.20) — 298KB
• exhibit1038secondamendment.htm (EX-10.38) — 136KB
• exhibit211subsidiaries2023.htm (EX-21.1) — 5KB
• exhibit231consent10-k2023.htm (EX-23.1) — 2KB
• exhibit311yearend2023.htm (EX-31.1) — 15KB
• exhibit312yearend2023.htm (EX-31.2) — 15KB
• exhibit321yearend2023.htm (EX-32.1) — 7KB
• exhibit971clawbackpolicyno.htm (EX-97.1) — 201KB
• 0001447362-24-000017.txt (&nbsp;) — 10112KB
• cstl-20231231.xsd (EX-101.SCH) — 57KB
• cstl-20231231_cal.xml (EX-101.CAL) — 115KB
• cstl-20231231_def.xml (EX-101.DEF) — 248KB
• cstl-20231231_lab.xml (EX-101.LAB) — 889KB
• cstl-20231231_pre.xml (EX-101.PRE) — 542KB
• cstl-20231231_htm.xml (XML) — 1264KB

Business

Item 1. Business 5

Risk Factors

Item 1A. Risk Factors 28

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 72

Cybersecurity

Item 1C. Cybersecurity 72

Properties

Item 2. Properties 74

Legal Proceedings

Item 3. Legal Proceedings 74

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 74 PART II. 75

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 75

[Reserved]

Item 6. [Reserved] 75

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 75

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 94

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 94

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 94

Controls and Procedures

Item 9A. Controls and Procedures 94

Other Information

Item 9B. Other Information 95

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 95 PART III. 96

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 96

Executive Compensation

Item 11. Executive Compensation 96

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 96

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 96

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 96 PART IV. 97

Exhibit and Financial Statement Schedules

Item 15. Exhibit and Financial Statement Schedules 97

Form 10-K Summary

Item 16. Form 10-K Summary 100

SIGNATURES

SIGNATURES 101 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F- 1 1 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. The forward-looking statements are contained principally in the sections entitled "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business." These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: estimates of our total addressable market ("TAM"), future revenue and addressable patient populations, expenses, capital requirements and our needs for additional financing; expectations with respect to reimbursement for our products, including third-party payor reimbursement and coverage decisions; anticipated cost, timing and success of our product candidates, and our plans to research, develop and commercialize new tests; the impact of geopolitical and macroeconomic developments, such as the Israel-Hamas war, and the ongoing conflict between Ukraine and Russia and related sanctions on our business; our ability to obtain funding for our operations, including funding necessary to complete the expansion of our operations and development of our pipeline products; the implementation of our business model and strategic plans for our products, technologies and business; expectations with respect to acquisitions of businesses, assets, products or technologies; our ability to manage and grow our business by expanding our

Business

Item 1. Business. As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, "Castle Biosciences", the "Company", "we", "us", and "our" refer to Castle Biosciences, Inc., a Delaware Corporation. Overview Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and in the treatment of mental health conditions. Since our inception in 2008, it has been our vision to transform disease management by keeping people first: patients, clinicians, employees and investors. This foundational strategy remains the guidepost for the direction of our company and the basis of long-term value creation. Our Testing Solutions Our tests are designed to deliver personalized information to help better inform care decisions. For our tissue based tests, we use multi-analyte assays with algorithmic analysis ("MAAA") to characterize an individual patient's biology to inform specific risk of progression. Test Portfolio and Market Overview The foundation of our business is our dermatologic cancer franchise. We currently offer five commercially available proprietary MAAA tests for use in the dermatologic, gastroenterology and ocular fields and a proprietary pharmacogenomic ("PGx") test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Maintaining commercial success for our existing test portfolio requires generating ongoing evidence, such as clinical use documentation, to support appropriate clinician adoption, reimbursement success and guideline inclusion. The clinical validity and utility of our test portfolio is supported by peer-reviewed publications and ongoing clinical studies. Collectively, approximately 140 peer-reviewed articles have been published demonstrating the analytical validity, clinical validity and clinical utility of the te